Première caractérisation moléculaire de Candida africana en Algérie

Racha, Boubekeur; Abdelouahed, Khaled; Adjmi-Hamoudi, Haiet; Yasmine, Belaid; Lamine, Lazri; Djazia, Dahlouk; Linda, B; Lyes, Cherfi; Mohsen, Sahraoui; Bachi, F.; Djafar, Bacha; Chaibi, Rachid

doi:10.1016/j.mycmed.2016.02.007

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study reports one of the largest clusters of C africana isolates from Iran to date and confirms that this pathogenic yeast makes a substantial contribution to vaginal infections in this country. However, although significant variations in C africana prevalence have been reported, between and across several countries worldwide, 12,15,23 our epidemiological data are in accordance with recent Iranian studies 20,38 and are quite similar to prevalence rates reported from other single centres in China (6.3%), 50 Italy (7.2%), 51 USA (7%) 52 and Algeria (10%) 53 indicating that this yeast may be more locally or regionally prevalent 23,41 . In fact, Turkey, which is geographically close to Iran, showed the lowest prevalence for C africana with two different studies reporting rates of 0% 54 and 0.8%, 46 respectively.…”

Section: Discussionsupporting

confidence: 91%

Molecular identification and antifungal susceptibility profiles of Candida dubliniensis and Candida africana isolated from vulvovaginal candidiasis: A single‐centre experience in Iran

Shokoohi

Javidnia

Mirhendi

et al. 2021

Mycoses

View full text Add to dashboard Cite

Background Vulvovaginal candidiasis (VVC) is a common and debilitating long‐term illness affecting million women worldwide. This disease is caused mainly by Candida albicans and a lesser extent by other species, including the two phylogenetically closely related pathogens Candida africana and Candida dubliniensis. Objectives In this study, we report detailed molecular epidemiological data about the occurrence of these two pathogenic yeasts in Iranian patients affected by VVC, or its chronic recurrent form (RVVC), and provide, for the first time, data on the antifungal activity of two new drugs, efinaconazole (EFN) and luliconazole (LUL). Methods A total of 133 vaginal yeast isolates, presumptively identified as C albicans by phenotypic and restriction analysis of rDNA, were further analysed by using a specific molecular method targeting the HWP1 gene. All C africana and C dubliniensis isolates were also tested for their in vitro susceptibility to a panel of modern and classical antifungal drugs. Results and Conclusions Based on the molecular results, among 133 germ‐tube positive isolates, we identify 119 C albicans (89.47%), 11 C africana (8.27%) and 3 C dubliniensis (2.26%) isolates. C africana and C dubliniensis showed low MIC values for most of the antifungal drugs tested, especially for EFN and LUL, which exhibited a remarkable antifungal activity. High MIC values were observed only for nystatin and terbinafine. Although C albicans remains the most common Candida species recovered from Iranian VVC/RVVC patients, our data show that its prevalence may be slightly overestimated due to the presence of difficult‐to‐identify closely related yeast, especially C africana.

show abstract